TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00440193
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
Study: NCT00440193
Drug: Enoxaparin followed by VKA
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 h before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
Study: NCT03337373
Drug: cisatracurium
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of 0.2 mg/kg intravenous bolus cisatracurium will be administered and blood samples will be taken before and at least 7 occasions post dose (at 1, 5, 10, 12, 15, 20, 30, and/or 60 minutes after a single bolus).
Study: NCT03075826
Drug: SGI-110
Normalized name: SGI-1776
DrugBank: SGI-1776 (DB12494)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneously at a dose of 60 mg/m2
Study: NCT03522506
Drug: TAK-925
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-925 intravenous infusion.
Study: NCT03890042
Drug: Dienogest group
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: VISANNE 2MG Tablet once daily
Study: NCT01944852
Drug: Icodextrin
Normalized name: Icodextrin
DrugBank: Icodextrin (DB00702)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00741845
Drug: intravaginal metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: high dose intravaginal metronidazole 750mg (with or without miconazole) to be compared to low dose intravaginal metronidazole 37.5mg
Study: NCT03071757
Drug: ABBV-368
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT03071757
Drug: ABBV-181
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT01651806
Drug: Tranexamic Acid standard dose
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uniform 1 gram dosing
Study: NCT01651806
Drug: Females Tranexamic Acid weighted dose
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weighted dose--20mg/kg of the drug will be given
Study: NCT01651806
Drug: Females receiving a uniform dose of TA
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive a uniform 1 gm dose of tranexamic acid prior to tourniquet release during a primary TKA.
Study: NCT01936090
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01936090
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03522506
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil tablets.
Study: NCT03522506
Drug: Modafinil Placebo
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil placebo-matching tablet.
Study: NCT00650806
Drug: Canagliflozin (JNJ-28431754)
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One 50 mg, 100 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
Study: NCT00116545
Drug: troglitazone
Normalized name: Troglitazone
DrugBank: Troglitazone (DB00197)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04765228
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib
Study: NCT02834793
Drug: Perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive perampanel in Randomization phase, open-label Extension A, and open-label Extension B.
Study: NCT00000303
Drug: Baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03402464
Drug: Icotinib combined dihydroaremisinin
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib should be taken by the patients continuously until disease progressed or intolerable toxicity. On day 1-3, oral dihydroaremisinin was given at 20mg per day, the dose of dihydroaremisinin is increased to 40mg daily on day 4 to 6, and 80mg twice daily until disease progressed or intolerable toxicity.
Study: NCT01386970
Drug: zidovudine 300mg and lamivudine 150mg as Combivir
Normalized name: lamivudine 150 MG / zidovudine 300 MG [Combivir]
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group
Study: NCT01523977
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Orally, daily days 1-32 per assigned dose level
Study: NCT01523977
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/m2/day orally 3 x daily days 4-32
Study: NCT01523977
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 mg/m2 IV daily on days 4, 11, 18, and 25
Study: NCT01523977
Drug: PEG-Asparaginase
Normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2,500 U/m2 IV 1 x daily on days 5 and 18
Study: NCT00406497
Drug: Difluprednate Ophthalmic Emulsion
Normalized name: Difluprednate Ophthalmic Emulsion
DrugBank: Difluprednate (DB06781)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01523977
Drug: Dexrazoxane
Normalized name: Dexrazoxane
DrugBank: Dexrazoxane (DB00380)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg/m2 IV on days 4 and 5
Study: NCT03020940
Drug: Cefuroxime Axetil Dispersible Tablets
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral. This product can be taken orally, can also be added to the amount of warm water after mixing evenly.~Adult general 0.25g (one time), 2 times a day, the general course of treatment for 5 to 10 days.~Severe Infection or suspected pneumonia, a 0.5g (once 2), 2 times a day; general urinary tract infection, a Times a 0.125g (one and a half tablets), 2 times a day; for patients with no complications of gonorrhea recommended dose of 1g (4 Tablets), a single taking.~Children generally a dose of 0.125g (one-half tablets), 2 times a day; for less than two years of age in the middle ear Inflammatory patients, a 0.125g (one half tablets), 2 times a day; for greater than two years of otitis media patients, one Times a 0.25g (one time), 2 times a day; more than 12 years of age in children, the same dose for adults
Study: NCT02511223
Drug: OLAPARIB
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 (mg) twice a day per os given every day until disease progression or toxicity
Study: NCT01149668
Drug: PCI-24781
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects enrolled in this study will receive PCI-24781 administered orally at the schedule and dosage from their prior protocol.
Study: NCT01049542
Drug: Astressin 2B
Normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After an initial saline washout, increasing doses of Astressin 2B (at 0.032, 0.32, 3.2, 32, 320 and 3200 pmol/min) will be infused, for 10 minutes at each dose,intra arterially using forearm venous occlusion plethysmography. Forearm blood flow will be measured with each incremental dose of Astressin 2B.
Study: NCT00221468
Drug: quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg of quetiapine on day 1 and titrated to a maximum dose of 400mg by day 4, with flexible dosing to 600mg by day 28. The total duration of treatment will be 84 days (12 weeks).
Study: NCT00015834
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00015834
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01206088
Drug: nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of nilotinib as 2nd line
Study: NCT01458041
Drug: Iloprost (Ilomedin, BAYQ6256)
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prescription and treatment of Iloprost will be decided by physicians
Study: NCT00742144
Drug: ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab (GSK1841157), a clear colorless liquid, is supplied in a glass vial. Each vial contains 100mg of ofatumumab in 5mL.
Study: NCT00003021
Drug: bizelesin
Normalized name: Bizelesin
DrugBank: Bizelesin (DB12352)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03472261
Drug: Botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Dysport
Study: NCT03835949
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Humanized monoclonal antibody to PD-L1
Study: NCT00217659
Drug: anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00217659
Drug: goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02456363
Drug: NSAIDs and sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: randomized case, combine with use of NSAIDs(-/+) and sulfasalazine(-/+)
Study: NCT00616538
Drug: Fluticasone Propionate 0.05%
Normalized name: FLUTICASONE PROPIONATE 0.05% CREAM
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Topical mid-strength steroid
Study: NCT01727024
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium via Respimat® device once a day
Study: NCT01727024
Drug: Indacaterol
Normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol via Breezhaler® device once a day
Study: NCT02549924
Drug: Resveratrol
Normalized name: Resveratrol
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol capsules, 500 mg 3 times daily with the first bite of each meal
Study: NCT00918736
Drug: sodium hyaluronate
Normalized name: sodium hyaluronate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
Study: NCT02204475
Drug: Grazoprevir/Elbasvir
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants take a fixed-dose combination of grazoprevir 100 mg and elbasvir 50 mg once daily (QD) by mouth (PO).
Study: NCT02204475
Drug: Boceprevir
Normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants take Boceprevir (BOC) 800 mg three times daily (TID) PO.
Study: NCT02204475
Drug: PegIntron
Normalized name: PegIntron
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants take 1.5 mcg/kg PegIntron (P) once weekly (QW) via subcutaneous injection.
Study: NCT02204475
Drug: Ribavarin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants take Ribavarin (R) 800-1400 mg (depending on body weight) twice daily (BID) PO.
Study: NCT03642132
Drug: Chemotherapy + avelumab followed by avelumab + talazoparib
Normalized name: Avelumab
DrugBank: Talazoparib (DB11760)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy Period Paclitaxel Carboplatin Avelumab~Maintenance Period Avelumab Talazoparib
Study: NCT03642132
Drug: Chemotherapy followed by talazoparib maintenance
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy Period Paclitaxel Carboplatin~Maintenance Period Talazoparib
Study: NCT02263677
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 60 day supply of 100mg Sitagliptin. The investigators will use an MRS (a non invasive method using magnets) to evaluate liver fat before and after subjects take a diabetes medication. The investigators will also collect a small amount of blood to measure liver, kidney and hormone functions. This will be done 4 times. Also, at the time of the subject gets their first dose of medication they will have a DEXA (low exposure x-ray often used in clinical practice to measure bone density and body composition).
Study: NCT01103375
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01103375
Drug: isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01159652
Drug: zaleplon
Normalized name: Zaleplon
DrugBank: Zaleplon (DB00962)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg
Study: NCT01159652
Drug: zolpidem extended release
Normalized name: zolpidem Extended Release Oral Tablet
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12.5 mg
Study: NCT00383929
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 32mg oral
Study: NCT00383929
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12.5 mg oral
Study: NCT00383929
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg oral
Study: NCT00381134
Drug: losartan 100 mg orally once daily
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04525066
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the treatment group received hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
Study: NCT02925650
Drug: Posiphen
Normalized name: Posiphen
DrugBank: Posiphen (DB15317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solid dosage form capsule
Study: NCT01258751
Drug: PF-05212377
Normalized name: PF-05212377
DrugBank: PF-05212377 (DB16044)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of up to 70 mg PF-05212377, delivered as .25 mg, 5 mg and/or 15 mg on study day 1
Study: NCT02268214
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets
Study: NCT02268214
Drug: Placebo for dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets
Study: NCT00457795
Drug: brimonidine 0.1% (Alphagan® P)
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine 0.1%, 1 drop three-times daily for 4 weeks
Study: NCT01352871
Drug: lipopolysaccharide
Normalized name: Lipopolysaccharide
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lipopolysaccharide 2ng/kg intravenously
Study: NCT00912756
Drug: cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg/day BID
Study: NCT03642132
Drug: Chemotherapy + bevacizumab followed by bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy Period Paclitaxel Carboplatin Bevacizumab~Maintenance Period Bevacizumab
Study: NCT03718559
Drug: Edoxaban Monotherapy
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Taking edoxaban (Lixiana™, Daiichi-Sankyo Inc.) 60mg once daily. The dose of edoxaban will be reduced to 30mg once daily in patients with estimated creatinine clearance 15≤CrCL≤50mL/min by Cockcroft-Gault equation or weight is ≤60kg.
Study: NCT03718559
Drug: Edoxaban plus Single Antiplatelet Agent
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Type of antiplatelet agent is dependant upon the investigator's discretion, but aspirin 100mg once daily or clopidogrel 75mg once daily was recommended.
Study: NCT01153659
Drug: E3810
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RAB ER 50 mg capsule once per day on Days 1-5
Study: NCT01153659
Drug: Aciphex (rabeprazole)
Normalized name: Aciphex
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aciphex (rabeprazole) 20 mg tablet once per day on Days 1-5
Study: NCT01153659
Drug: Nexium (esomeprazole)
Normalized name: Nexium
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nexium (esomeprazole) 40 mg capsule once per day on Days 1-5
Study: NCT04122339
Drug: MAX-10181
Normalized name: Bronkaid Max
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1.
Study: NCT00209560
Drug: fospropofol disodium
Normalized name: Fospropofol disodium
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04498260
Drug: Local steroid - triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (triamcinolone acetonide)
Study: NCT00805857
Drug: Tipranavir
Normalized name: Tipranavir
DrugBank: Tipranavir (DB00932)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02101710
Drug: Elantan SR 60 mg
Normalized name: Elantan
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Trade Name: Elantan~* Active Substance: Isosorbide 5-mononitrate~* Pharmaceutical form: Tablet~* Concentration: 60 mg~* Route of Administration: Oral administration
Study: NCT02101710
Drug: Imdur SR 60 mg
Normalized name: isosorbide mononitrate Extended Release Oral Tablet [Imdur]
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Trade Name: Elantan~* Active Substance: Isosorbide 5-mononitrate~* Pharmaceutical form: Tablet~* Concentration: 60 mg~* Route of Administration: Oral administration
Study: NCT01158170
Drug: Erlotinib /Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib 150mg/d or Gefitinib 250mg/d until disease progression or intolerable toxicity
Study: NCT00016406
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00233675
Drug: GABITRIL (tiagabine hydrochloride; CEP-6671)
Normalized name: tiagabine hydrochloride 12 MG [Gabitril]
DrugBank: Tiagabine (DB00906)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00036608
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00233454
Drug: Midostaurin
Normalized name: Midostaurin
DrugBank: Midostaurin (DB06595)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Midostaurin is a broad-spectrum protein kinase inhibitor, acting on conventional PKC isoforms (α, β, γ); PDFRβ; VEGFR2; Syk; PKCη; Flk-1; Flt3; Cdk1/B; PKA; c-Kit; c-Fgr; c-Src; VEGFR1; and EGFR
Study: NCT02317744
Drug: Naltrexone and bupropion combination
Normalized name: bupropion and naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01363349
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01958489
Drug: Evacetrapib
Normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02269085
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase I Starting Dose: 420 mg by mouth daily on Days 1 - 28 of a 28-day cycle.~Phase II Starting Dose: MTD from Phase I.
Study: NCT02269085
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8 ,9, 15 and 16 in Cycles 1 - 12, and Days 1,2 and 15,16 of Cycle 13 and beyond.~Phase II Starting Dose: MTD from Phase I.
Study: NCT00741026
Drug: Olanzapine 10 mg po qhs for 3 days
Normalized name: olanzapine 3 MG
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (1) 10 mg tablets administered orally before bed for three consecutive evenings (Total Dose = 30 mg, 3 tablets)
Study: NCT03569345
Drug: AFXl-assisted ingenol mebutate delivery
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive ablative fractional laser (AFXl)-assisted ingenol mebutate (IM) as a treatment for their cutaneous basal cell carcinoma (BCC). Treatment areas consisting of tumors and a 5 mm margin will undergo AFXl exposure (CO2 laser) followed by IM 0.015% or 0.05% under occlusion for 2-3 days. .~local skin reactions are monitored at baseline (day1), day 3/4, day 8, day 15, day 29, day 90, and tumor response monitored at baseline, day 29, and day 90. An additional repeat AFXl-IM treatment on day 29 will be offered if tumors persist, based on clinical evaluation and imaging on day 30.
Study: NCT01379144
Drug: latanoprost 75 ug
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit.